Assembly Biosciences, Inc. (NASDAQ:ASMB) Director John G. Mchutchison Sells 1,206 Shares

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Free Report) Director John G. Mchutchison sold 1,206 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $13.07, for a total value of $15,762.42. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $277,358.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Assembly Biosciences Stock Performance

Shares of NASDAQ:ASMB traded up $0.60 during midday trading on Tuesday, hitting $13.50. The company’s stock had a trading volume of 37,039 shares, compared to its average volume of 29,639. The stock has a market capitalization of $73.98 million, a price-to-earnings ratio of -0.78 and a beta of 0.57. The stock’s 50 day simple moving average is $12.22 and its 200 day simple moving average is $10.60. Assembly Biosciences, Inc. has a fifty-two week low of $7.69 and a fifty-two week high of $20.04.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ASMB shares. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a report on Monday. StockNews.com lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, March 28th.

View Our Latest Research Report on ASMB

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Assembly Biosciences during the first quarter worth about $27,000. JPMorgan Chase & Co. lifted its stake in Assembly Biosciences by 15,633.0% during the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 14,695 shares during the period. Prudential Financial Inc. bought a new position in Assembly Biosciences during the second quarter worth about $36,000. Tower Research Capital LLC TRC lifted its stake in Assembly Biosciences by 110.2% during the third quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 8,992 shares during the period. Finally, UBS Group AG lifted its stake in Assembly Biosciences by 110.0% during the fourth quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 12,576 shares during the period. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.

Featured Stories

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.